Is 68Ga–Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma?
Canan Can, Cihan Gündoğan, Halil Kömek
Abstract
ABSTRACT: We present the case of a 75-year-old man with osteosarcoma of the sternum in whom 68Ga-prostate-specific membrane antigen (PSMA) PET/CT showed high radiotracer activity in the primary tumor and metastatic lesions than 18F-FDG PET/CT. The present case shows that 68Ga-PSMA PET/CT is very useful for staging of osteosarcoma due to in vivo expression of PSMA. 68Ga-PSMA PET/CT can have potential effects on prognosis and in response assessment following treatment in osteosarcoma. The use of PSMA-targeted radioligand treatments may be beneficial especially in metastatic chemorefractory osteosarcoma.
Topics & Concepts
MedicineOsteosarcomaGlutamate carboxypeptidase IIPET-CTRadioligandPositron emission tomographyNuclear medicineIn vivoProstate cancerMetastasisPositron Emission Tomography-Computed TomographyRadiologyCancer researchInternal medicineCancerReceptorBiotechnologyBiologySarcoma Diagnosis and TreatmentRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research